tag:www.gov.uk,2005:/drug-safety-updateDrug Safety Update about Nutrition and dietetics2025-01-28T14:00:20+00:00HM Governmenttag:www.gov.uk,2005:/drug-safety-update/glp-1-and-dual-gip-slash-glp-1-receptor-agonists-potential-risk-of-pulmonary-aspiration-during-general-anaesthesia-or-deep-sedation2025-01-28T14:00:20+00:00GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation Healthcare professionals should be aware of the potential risk of pulmonary aspiration in patients using GLP-1 or dual GIP/GLP-1 receptor agonists who undergo surgery or procedures with general anaesthesia or deep sedation.tag:www.gov.uk,2005:/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse2024-10-24T11:00:32+01:00GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuseHealthcare professionals are reminded to inform patients about the common and serious side effects associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs). tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-september-20242024-10-24T11:00:11+01:00Letters and medicine recalls sent to healthcare professionals in September 2024 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-march-20242024-04-29T16:03:09+01:00Letters and medicine recalls sent to healthcare professionals in March 2024A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-january-20242024-02-20T11:01:30+00:00Letters and medicine recalls sent to healthcare professionals in January 2024A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. tag:www.gov.uk,2005:/drug-safety-update/omega-3-acid-ethyl-ester-medicines-omacor-slash-teromeg-1000mg-capsules-dose-dependent-increased-risk-of-atrial-fibrillation-in-patients-with-established-cardiovascular-diseases-or-cardiovascular-risk-factors2024-01-22T15:40:54+00:00Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factorsSystematic reviews and meta-analyses of randomised controlled trials have highlighted a dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors�tag:www.gov.uk,2005:/drug-safety-update/ozempicv-semaglutide-and-saxenda-liraglutide-vigilance-required-due-to-potentially-harmful-falsified-products2023-11-23T14:15:41+00:00Ozempic�(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products Falsified, potentially harmful Ozempic� and Saxenda products have been found in the UK. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-may-20222022-06-20T16:38:29+01:00Letters and medicine recalls sent to healthcare professionals in May 2022A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devicestag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-january-20222022-02-15T14:06:11+00:00Letters and medicine recalls sent to healthcare professionals in January 2022A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-december-20212022-01-18T13:18:06+00:00Letters and medicine recalls sent to healthcare professionals in December 2021A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-april-20212021-05-19T13:57:21+01:00Letters and medicine recalls sent to healthcare professionals in April 2021A summary of letters and recent medicine recalls and notifications sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-march-20212021-04-27T14:22:10+01:00Letters and medicine recalls sent to healthcare professionals in March 2021A summary of letters and recent medicine recalls and notifications sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-june-20202020-07-31T11:39:50+01:00Letters and drug alerts sent to healthcare professionals in June 2020A summary of letters and drug alerts recently sent to healthcare professionals.
tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-october-20192019-11-21T14:56:49+00:00Letters and drug alerts sent to healthcare professionals in October 2019Letters were sent about quadrivalent influenza vaccine, fentanyl ampoules, and Volibris (ambrisentan), and a number of pharmacy-level recalls were issued for ranitidine-containing products. Other alerts issued in October 201�tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-september-20192019-10-18T15:39:23+01:00Letters and drug alerts sent to healthcare professionals in September 2019Letters were issued about parenteral nutrition products, ranibizumab, ingenol mebutate gel, adrenaline auto-injectors, and fingolimod. Recall alerts were recently issued about ranitidine, aripiprazole, and bisacodyl.tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-april-20192019-05-17T14:53:45+01:00Letters and drug alerts sent to healthcare professionals in April 2019Letters were sent about alemtuzumab (Lemtrada), Selenase (sodium selenite pentahydrate), and Erelzi� (etanercept). tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-march-20192019-04-16T15:53:23+01:00Letters and drug alerts sent to healthcare professionals in March 2019Letters were sent about Xeljanz� (tofacitinib), ranitidine, Nulojix (belatacept), fluoroquinolone antibiotics, Genvoya�, Stribild�, Tybost, and belimumab (Benlysta�). Drug alerts were issued about Accord losartan potassium c�tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-august-20182018-09-25T14:01:36+01:00Letters and drug alerts sent to healthcare professionals in August 2018Letters were sent about daclizumab beta (Zinbryta�), alteplase (Actilyse), Esmya (ulipristal acetate), and Xofigo� (radium-223-dichloride). MHRA issued alerts and recalls for batches of Nutriflex Omega Special 2500 ml and Nu�tag:www.gov.uk,2005:/drug-safety-update/medical-device-alerts-issued-in-july-20182018-08-24T14:54:33+01:00Medical Device Alerts issued in July 2018Alerts were recently issued about Novaline haemodialysis bloodlines used with Baxter/Gambro haemodialysis machines and Alaris and Asena enteral syringe pumps tag:www.gov.uk,2005:/drug-safety-update/medicines-taken-during-pregnancy-please-report-suspected-adverse-drug-reactions-including-in-the-baby-or-child-on-a-yellow-card2018-07-17T14:35:39+01:00Medicines taken during pregnancy: please report suspected adverse drug reactions, including in the baby or child, on a Yellow CardReport to the Yellow Card Scheme suspected adverse reactions associated with medicines taken during pregnancy experienced by women or the baby or child. Obstetricians and midwives have a particularly important role in provid�tag:www.gov.uk,2005:/drug-safety-update/antiretroviral-medicines-updated-advice-on-body-fat-changes-and-lactic-acidosis2015-12-14T16:17:53+00:00Antiretroviral medicines: updated advice on body-fat changes and lactic acidosis With the exception of medicines containing zidovudine, stavudine, or didanosine, product information will no longer include warnings on fat redistribution or lactic acidosis.tag:www.gov.uk,2005:/drug-safety-update/ferumoxytol-rienso-intravenous-iron-no-longer-available-for-use2015-03-30T11:58:39+01:00Ferumoxytol (Rienso) intravenous iron no longer available for useThe licence-holder of ferumoxytol has voluntarily withdrawn it from the UK market for commercial reasons.tag:www.gov.uk,2005:/drug-safety-update/corticosteroids-e-learning-module-launched2015-03-30T11:57:32+01:00Corticosteroids e-learning module launched The new module helps clinicians understand how to identify, manage and avoid side effects when using corticosteroids.tag:www.gov.uk,2005:/drug-safety-update/letters-sent-to-healthcare-professionals-since-november-20142015-02-16T15:32:29+00:00Letters sent to healthcare professionals since November 2014Since November 2014, letters were sent regarding vismodegib (Erivedge �), chlorhexidine solutions, carbocisteine oral liquid (Mucodyne Paediatric 125mg/5ml), regadenoson (Rapiscan), a parenteral nutrition emulsion (Triomel),�tag:www.gov.uk,2005:/drug-safety-update/ferumoxytol-risk-of-serious-hypersensitivity-reactions-contraindicated-if-any-drug-allergy-administer-via-infusion2014-12-11T14:37:47+00:00Ferumoxytol: risk of serious hypersensitivity reactions—contraindicated if any drug allergy; administer via infusion New recommendations are being introduced to minimise the risk of serious hypersensitivity reactions with ferumoxytol. tag:www.gov.uk,2005:/drug-safety-update/domperidone-no-longer-available-without-prescription2014-12-11T14:37:44+00:00Domperidone: no longer available without prescriptionPeople now need to have a medical assessment before taking domperidone to determine if it is suitable for them due to the risk of cardiac side effects.tag:www.gov.uk,2005:/drug-safety-update/adrenaline-auto-injector-advice-for-patients2014-12-11T14:37:05+00:00Adrenaline auto-injector advice for patientsAfter every use, an ambulance should be called even if symptoms are improving, the individual should lie down with legs raised and, if at all possible, should not be left alone.tag:www.gov.uk,2005:/drug-safety-update/domperidone-risks-of-cardiac-side-effects2014-12-11T14:37:02+00:00Domperidone: risks of cardiac side effectsIndication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use.tag:www.gov.uk,2005:/drug-safety-update/orlistat-theoretical-interaction-with-antiretroviral-hiv-medicines2014-12-11T14:36:46+00:00Orlistat: theoretical interaction with antiretroviral HIV medicinesInitiate orlistat treatment only after careful consideration of the possible impact on efficacy of antiretroviral HIV medicines.tag:www.gov.uk,2005:/drug-safety-update/intravenous-iron-and-serious-hypersensitivity-reactions2014-12-11T14:35:47+00:00Intravenous iron and serious hypersensitivity reactionsClarification of advice on new recommendations regarding initial test dose.tag:www.gov.uk,2005:/drug-safety-update/intravenous-iron-and-serious-hypersensitivity-reactions-strengthened-recommendations2014-12-11T14:35:24+00:00Intravenous iron and serious hypersensitivity reactions: strengthened recommendationsNew strengthened recommendations to manage and minimise risk.tag:www.gov.uk,2005:/drug-safety-update/intravenous-0-18-saline-4-glucose-solution-hypotonic-saline-in-children-reports-of-fatal-hyponatraemia2014-12-11T14:33:43+00:00Intravenous 0.18% saline/4% glucose solution (‘hypotonic saline�) in children: reports of fatal hyponatraemiaDo not use in children aged 16 years or less, except in specialist settings under expert medical supervision.tag:www.gov.uk,2005:/drug-safety-update/unlicensed-imported-vitamin-d-colecalciferol-capsules-potential-peanut-oil-and-soya-oil-allergens2014-12-11T14:32:44+00:00Unlicensed imported vitamin D (colecalciferol) capsules: potential peanut oil and soya oil allergensHealthcare professionals should be aware that these capsules contain potential allergens.tag:www.gov.uk,2005:/drug-safety-update/calcium-and-vitamin-d-no-prescribing-changes2014-12-11T14:32:03+00:00Calcium and vitamin D: no prescribing changesStudies of cardiovascular risk don’t support prescribing changes.tag:www.gov.uk,2005:/drug-safety-update/orlistat-safety-update2014-12-11T14:28:26+00:00Orlistat safety updateA recent Europe-wide review of the safety information for alli has led to a number of updates, which bring the product information in line with that for Xenical.tag:www.gov.uk,2005:/drug-safety-update/sibutramine-suspension-of-eu-licences-recommended2014-12-11T14:28:21+00:00Sibutramine: suspension of EU licences recommended Evidence indicates risks outweigh benefits.tag:www.gov.uk,2005:/drug-safety-update/ecoflac-infusion-solutions-risk-of-air-embolism2014-12-11T14:24:01+00:00Ecoflac infusion solutions: risk of air embolismTo avoid the risk of air embolism, these products should not be infused under pressure.tag:www.gov.uk,2005:/drug-safety-update/pabrinex-allergic-reactions2014-12-11T14:23:47+00:00Pabrinex: allergic reactionsRare occurrence of serious allergic reactions should not preclude use of parenteral thiamine in patients who need treatment by this route of administration.